Publications by authors named "D J Schaer"
Background: Preclinical studies indicate that the systemic application of C1-inhibitor, clinically used to treat hereditary angioedema, reduces secondary brain injury after ischemic stroke. This study assessed the effect of C1-inhibitor on secondary brain injury after hemorrhagic stroke.
Methods: We used an established striatal whole-blood injection mouse model to mimic intracerebral hemorrhage-related secondary brain injury.
Objective: To explore the feasibility and effect of a nurse-led integrated care intervention on health-related quality of life (QoL) and unplanned 90-day rehospitalisation in patients hospitalised due to acute exacerbation of COPD (AECOPD).
Method: A monocentric non-randomized parallel cluster design was applied. The primary endpoint was the difference between Chronic Respiratory Questionnaire (CRQ) Mastery Scores at hospital discharge and 13 weeks post-discharge.
Background: PF-06952229 is a selective small-molecule inhibitor of transforming growth factor-β (TGF-β) receptor 1. We evaluated its antitumor activity in preclinical studies and its safety, tolerability, pharmacokinetics, and pharmacodynamics in a phase I study (NCT03685591).
Patients And Methods: In vitro and in vivo preclinical studies were conducted.
Article Synopsis
- Acute kidney injury (AKI) occurs in 20-30% of cardiac surgery patients using cardiopulmonary bypass (CPB), and it's linked to hemolysis caused by the CPB process.
- The release of cell-free hemoglobin leads to oxidative stress, reduced nitric oxide levels, and inflammation, which all contribute to kidney damage.
- New treatments like haptoglobin, nitric oxide, and antioxidants show promise in mitigating hemoglobin-related toxicity and preventing AKI, with encouraging clinical evidence suggesting these approaches could be effective.
Metabolic reprogramming and mitochondrial dynamics are pivotal in prostate cancer (PCa) progression and treatment resistance, making them essential targets for therapeutic intervention. In this study, we investigated the effects of the androgen receptor antagonist apalutamide (ARN) and the mitochondrial electron transport chain complex I inhibitor IACS-010759 (IACS) on the mitochondrial network architecture and dynamics in PCa cells. Treatment with ARN and/or IACS induced significant changes in mitochondrial morphology, particularly elongation, in androgen-sensitive PCa cells.
View Article and Find Full Text PDF